The recent escalation of trade tensions under United States President Donald Trump has significantly increased uncertainty ...

CoreWeave said on Thursday it was targeting a valuation of up to $26 billion in its U.S. initial public offering, as the ...

Marketing and sales expenses increased by €2.8 million in 2024 compared to 2023, as 2024 represented the first full year of commercial efforts for GOHIBIC (vilobelimab) in the United States. In 2023, ...

The offering is expected to be a key test of appetite for AI-focused companies after the launch of Chinese startup DeepSeek's ...

A league-record crowd is anticipated to attend the Barclays Women's Championship fixture, with the club also set to break ...

To ensure that this relaxation is not misused, the regulator has also proposed a cooling off period between the grant of such ...

Since the emergence of DeepSeek, Chinese AI has grabbed headlines and been the talk of tech bosses around the globe. However, ...

The president disbanded the Institute of Museum and Library Services. Academic researchers, librarians and museum ...

The shares are being offered by Akebia pursuant to a shelf registration statement that was filed with the Securities and Exchange Commission (“SEC”) on September 3, 2024 and declared effective by the ...

CoreWeave is looking to ask investors to pay $47 to $55 per share, when it starts marketing its initial public offering this week, Reuters reports, citing sources. -- The price range would mean an ...

CoreWeave, the artificial intelligence startup backed by Nvidia, is planning to ask investors to pay $47 to $55 for each of ...

Shares of Akebia Therapeutics fell after the company said it has commenced an underwritten public offering. The stock sank 21% to $2.24 in after-hours trading Wednesday. Shares ended the regular ...